Peter J. Selby

ORCID: 0000-0002-3782-069X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Renal cell carcinoma treatment
  • Virus-based gene therapy research
  • Cancer Genomics and Diagnostics
  • Immunotherapy and Immune Responses
  • Cancer survivorship and care
  • CAR-T cell therapy research
  • Renal and related cancers
  • Health Systems, Economic Evaluations, Quality of Life
  • Advanced Proteomics Techniques and Applications
  • Palliative Care and End-of-Life Issues
  • Economic and Financial Impacts of Cancer
  • Global Cancer Incidence and Screening
  • Bladder and Urothelial Cancer Treatments
  • Childhood Cancer Survivors' Quality of Life
  • Cancer Research and Treatments
  • Immune Cell Function and Interaction
  • Epigenetics and DNA Methylation
  • Multiple Myeloma Research and Treatments
  • Patient-Provider Communication in Healthcare
  • Viral gastroenteritis research and epidemiology
  • Advances in Oncology and Radiotherapy
  • Mass Spectrometry Techniques and Applications
  • Molecular Biology Techniques and Applications
  • Ovarian cancer diagnosis and treatment
  • Lymphoma Diagnosis and Treatment

University of Leeds
2016-2025

University of Lincoln
2021-2025

University of Toronto
2024-2025

Centre for Addiction and Mental Health
2023-2025

British Columbia Centre on Substance Use
2025

Waypoint Centre for Mental Health Care
2025

Université de Montréal
2025

University of British Columbia
2025

St James's University Hospital
2015-2024

Dolby (Netherlands)
2024

High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating high-dose yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited.

10.1056/nejmoa022340 article EN New England Journal of Medicine 2003-05-07

To examine the effects on process of care and patient well-being, regular collection use health-related quality-of-life (HRQL) data in oncology practice.In a prospective study with repeated measures involving 28 oncologists, 286 cancer patients were randomly assigned to either intervention group (regular completion European Organization for Research Treatment Cancer-Core Quality Life Questionnaire version 3.0, Hospital Anxiety Depression Scale touch-screen computers clinic feedback results...

10.1200/jco.2004.06.078 article EN Journal of Clinical Oncology 2004-02-14

PURPOSE: We aimed to estimate the prevalence and types of anxiety disorders diagnosed according standardized criteria in cancer patients, compare screening tools detecting them, examine their demographic, oncologic, psychosocial associations. METHODS: In this cross-sectional observational study 178 subjects with lymphoma, renal cell carcinoma, malignant melanoma, or plasma dyscrasia, we related responses questionnaires (administered by computer touch-screen) measuring psychological symptoms,...

10.1200/jco.2002.08.549 article EN Journal of Clinical Oncology 2002-07-15

Despite recent developments in bottom-up proteomics, the need still exists a fast, uncomplicated, and robust method for comprehensive sample processing especially when applied to low protein amounts. The suspension trapping combines advantage of efficient SDS-based extraction with rapid detergent removal, reactor-type digestion, peptide cleanup. Proteins are solubilized SDS. is acidified introduced into tip incorporating depth filter hydrophobic compartments, filled neutral pH methanolic...

10.1002/pmic.201300553 article EN PROTEOMICS 2014-02-17

To evaluate our clinical experience with percutaneous image-guided radiofrequency ablation (RFA) of 200 renal tumours in a large tertiary referral university institution.Image-guided RFA (ultrasonography or computed tomography [CT]) 165 patients from June 2004 to 2012 was prospectively evaluated. Institutional Review Board approval granted. The treatment response and technical success were defined by absence contrast enhancement within the tumour on enhanced CT magnetic resonance imaging....

10.1111/bju.12349 article EN cc-by-nc-nd BJU International 2013-07-02
Janet E. Brown Kara‐Louise Royle Walter M. Gregory Christy Ralph Anthony Maraveyas and 94 more Omar Din Timothy Eisen Paul Nathan Tom Powles Richard Griffiths Robert J. Jones Naveen Vasudev Matthew Wheater Abdel Hamid Tom Waddell R. McMenemin Poulam M. Patel James Larkin Guy Faust Adam Martin Jayne Swain Janine Bestall Christopher McCabe David Meads Vicky Goh Tze Min Wah Julia Brown Jenny Hewison Peter J. Selby Fiona Collinson Judith Carser Gopalakrishnan Srinivasan Fiona Thistlewaite Ashraf Azzabi Mark Beresford David Farrugia M. Decatris Carys Thomas Joanna Gale James J McAleer Alison Clayton Ekaterini Boleti T. Geldart Santhanam Sundar J.F. Lester Nachi Palaniappan Mohan Hingorani Khaliq Rehman Mohammad Adil Khan Naveed Sarwar Janine Graham Alastair Thomson Narayanan Srihari Denise Sheehan R. Srinivasan Omar Khan Andrew Stockdale Jane Worlding Stergios Boussios N Stuart Carey MacDonald-Smith Falalu Danwata Duncan McLaren Aravindhan Sundaramurthy Anna Lydon S. Beesley Kathryn Lees Mohini Varughese Emma Gray Angela C Scott Mark Baxter Anna Mullard Pasquale F. Innominato Gaurav Kapur Anil Kumar Natalie Charnley Caroline Manetta Prabir Chakraborti Prantik Das Sarah Rudman Henry F. Taylor Christos Mikropoulos Martin Highley D. Muthukumar Anjali Zarkar Roy Vergis Seshadri Sriprasad Patryk Brulinski Amanda Clarke Richard Osbourne Melanie Harvey Renata Dega Geoffrey Sparrow Urmila Barthakur Erica Beaumont Caroline Manetta Agnieszka Michael Emilio Porfiri Faisal Azam Ravi Kodavtiganti

10.1016/s1470-2045(22)00793-8 article EN cc-by The Lancet Oncology 2023-02-13

To evaluate alternative automated methods of collecting data on quality life (QOL) in cancer patients. After initial evaluation a range technologies, we compared computer touch-screen questionnaires with paper scanned by optical reading systems terms patients' acceptance, quality, and reliability.In randomized cross-over trial, 149 patients completed the European Organization for Research Treatment Cancer Quality Life Questionnaire-Core 30, version 2.0 (EORTC QLQ-C30), Hospital Anxiety...

10.1200/jco.1999.17.3.998 article EN Journal of Clinical Oncology 1999-03-01

Exosomes are 40-100 nm vesicles released by numerous cell types and thought to have a variety of roles depending on their origin. derived from antigen presenting cells been shown be capable initiating immune responses in vivo eradicating established tumours murine models. Tumour-derived exosomes can utilised as source tumour for cross-priming T-cells thus interest use anti-tumour immunotherapy. Further exploration into the protein composition may increase our understanding potential this...

10.1002/pmic.200400876 article EN PROTEOMICS 2004-10-11

Genetic and epigenetic changes in the von Hippel-Lindau (VHL) tumor suppressor gene are common sporadic conventional renal cell carcinoma (cRCC). Further insight into clinical significance of these may lead to increased biological understanding identification subgroups patients differing prognostically or who benefit from specific targeted treatments. We have comprehensively examined VHL status tissue samples 115 undergoing nephrectomy, including 96 with cRCC. In cRCC, loss heterozygosity...

10.1158/0008-5472.can-05-3074 article EN Cancer Research 2006-02-15

High dose melphalan (HDM, 140 mg/m2 i.v.) has been evaluated in 58 patients under 63 years with multiple myeloma. Among previously untreated 11/41 (27%) entered a complete remission (CR: no measurable myeloma protein and normal bone marrow) 21 (51%) partial (more than 50% reduction improvement all other features). Median duration of is 19 months. Two who had responded to previous conventional treatment CR after HDM. 15 failed on chemotherapy the response rate was 66% including two CRs....

10.1111/j.1365-2141.1987.tb06890.x article EN British Journal of Haematology 1987-05-01

A primary objective of many protein expression studies is to define patterns that can distinguish between normal and diseased states, enabling a better understanding molecular events associated with disease development progression ultimately potentially finding novel markers or therapeutic targets. Exploration confirmation proteins often done using Western blotting normalization against “housekeeping proteins”, such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β-actin, β-tubulin,...

10.1002/pmic.200400941 article EN PROTEOMICS 2005-01-03

Abstract Renal cell carcinoma (RCC) is the tenth most common cancer although incidence increasing. The main clinical problems stem from relatively late presentation of many patients due to often asymptomatic nature illness, and relative insensitivity metastatic disease conventional chemotherapy radiotherapy. Despite increasing knowledge some genetic changes underlying sporadic renal such as those involving Von Hippel Lindau (VHL) gene, pathophysiological are ill‐defined there remains a need...

10.1002/pmic.200300464 article EN PROTEOMICS 2003-08-01

Profiling approaches in proteomics, such as surface-enhanced laser desorption/ionization (SELDI) mass spectrometry, are used disease marker discovery. The aim of this study was to investigate the potential influence selected preanalytical factors on results obtained.Plasma samples anticoagulated with EDTA, citrate, or heparin, and serum from healthy volunteers were profiled by SELDI CM10, immobilized metal affinity capture (IMAC) array copper, H50 chip surfaces. Using linear mixed-effects...

10.1373/clinchem.2005.051417 article EN Clinical Chemistry 2005-07-07
Mark P. Purdue Mattias Johansson Diana Zélénika Jorge R. Toro Ghislaine Scélo and 95 more Lee E. Moore Egor Prokhortchouk Xifeng Wu Lambertus A. Kiemeney Valérie Gaborieau Kevin B. Jacobs Wong‐Ho Chow Давид Заридзе В. Б. Матвеев Jan Lubiński Joanna Trubicka Neonila Szeszenia‐Dąbrowska Jolanta Lissowska Péter Rudnai Eleonóra Fabiánová Alexandru Bucur Vladimír Bencko Lenka Foretová Vladimí­r Janout Paolo Boffetta Joanne S. Colt Faith G. Davis Kendra Schwartz Rosamonde E. Banks Peter J. Selby Patricia Harnden Christine D. Berg Ann W. Hsing Robert L. Grubb Heiner Boeing Paolo Vineis Françoise Clavel-Chapelon Domenico Palli ­Rosario ­Tumino Vittorio Krogh Salvatore Panico Eric J. Duell J. Ramón Quirós María‐José Sánchez Carmen Navarro Eva Ardanáz Miren Dorronsoro Kay‐Tee Khaw Naomi E. Allen H. Bas Bueno-de-Mesquita Petra H. Peeters Dimitrios Trichopoulos Jakob Linseisen Börje Ljungberg Kim Overvad Anne Tjønneland Isabelle Romieu Elio Ríboli Anush Mukeria Oxana Shangina Victoria L. Stevens Michael J. Thun W. Ryan Diver Susan M. Gapstur Paul D.P. Pharoah Douglas F. Easton Demetrius Albanes Stephanie J. Weinstein Jarmo Virtamo Lars J. Vatten Kristian Hveem Inger Njølstad Grethe S. Tell Camilla Stoltenberg Rajiv Kumar Kvetoslava Koppová Olivier Cussenot Simone Benhamou Egbert Oosterwijk Sita H. Vermeulen Katja K.H. Aben Saskia L. van der Marel Yuanqing Ye Christopher G. Wood Xia Pu Alexander M. Mazur Eugenia Boulygina Nikolay Chekanov Mario Foglio Doris Lechner Marta Gut Simon Heath Hélène Blanché Amy Hutchinson Gilles Thomas Zhaoming Wang Meredith Yeager Joseph F. Fraumeni K. G. Skryabin James McKay

10.1038/ng.723 article EN Nature Genetics 2010-12-05

PURPOSE We report the results of intensive chemotherapy with high-dose melphalan (HDM) following conventional-dose cytoreductive in previously untreated patients myeloma. PATIENTS AND METHODS From 1986 to 1991, 53 myeloma received HDM 200 mg/m2 plus methylprednisolone 1.5 g daily (MP) for 5 days autologous bone marrow transplantation (ABMT) after chemotherapy. RESULTS At time administration, responses induction therapy were complete remission (CR) nine patients, partial (PR) 38, and no...

10.1200/jco.1994.12.4.759 article EN Journal of Clinical Oncology 1994-04-01
Coming Soon ...